A research initiative developing highly potent, species-selective, and orally active reversible inhibitors of the Plasmodium falciparum 20S proteasome. Designed to treat malaria while avoiding human proteasome cross-inhibition, these candidates offer a novel therapeutic path with a low risk of drug resistance. The project seeks development partners to advance these lead compounds through preclinical stages.
This research initiative focuses on the development of species-selective, reversible inhibitors of the Plasmodium falciparum 20S proteasome as a novel strategy to combat malaria. By targeting a unique, non-conserved site at the parasite proteasome subunit interface, these inhibitors offer a promising approach to treat malaria while avoiding cross-inhibition of human proteasomes, thereby minimizing potential toxicity. This project provides a collaborative opportunity for partners to engage in the optimization of advanced lead compounds, such as piperidine carboxamide derivatives, which have demonstrated potent antimalarial activity and promising oral bioavailability.
The inhibitors are designed to bind non-covalently to the parasite proteasome at a pocket located at the beta5/beta6/beta3 subunit interface, which is distinct from human proteasome isomers. Key features include:
The technology is currently in development (TRL 4). Research has successfully identified potent lead candidates through phenotypic screening, iterative structure-activity relationship (SAR) studies, and in vivo pharmacokinetic validation in mouse models. The mechanism of action is well-characterized via cryo-EM, and the molecules are ready for advanced preclinical optimization.
UT Southwestern Medical Center is a leading academic medical center within the University of Texas System, combining biomedical research, education, and a major clinical enterprise in Dallas. Co-located hospitals and outpatient networks provide direct access to clinicians, diverse patient populations, and real‑world data, enabling rapid design and execution of clinical studies. Companies engage through on‑campus incubator space, shared core facilities, and collaboration models that range from sponsored research to multi‑site trials. Research is supported primarily by NIH, with additional competitive federal awards from other national agencies. A dedicated technology transfer office streamlines IP protection, licensing, and startup formation to accelerate commercialization.